

*The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.*

As a precautionary measure, Lupin Pharmaceuticals, Inc. is initiating a **recall** of lots **F305184, Expiry: July 2025, F305185, Expiry: July 2025** and **F305186, Expiry: July 2025** of **Cefdinir for Oral Suspension USP 250 mg/5 mL** to the **retail** level. These lots are being recalled due to two complaints indicating partially sealed bottle.

Inappropriate sealing of bottle may lead to leakage of product content to the outside of the bottle, thus could result in decrease of therapeutic effect (sub therapeutic response).

The recalled lots were distributed between September 2023 to February 2024 to wholesalers/ distributors and drug chain stores nationwide.

**Cefdinir for Oral Suspension USP 250 mg/5 mL supplied as:**

<b>Strength</b>	<b>Lot</b>	<b>Expiry</b>	<b>NDC</b>	<b>Description</b>
	F305184	July -2025		
	F305185	July -2025		Off-white to creamish powder, free from lumps and agglomerates, forming off-white to creamish suspension with characteristic odor on constitution.
250 mg/ 5 mL	F305186	July -2025	68180-723-04	